Founded in 2014 and based in Maple Grove, Minnesota, StemoniX develops and manufactures human-induced pluripotent stem (iPS) cell-derived cardiac and neural platforms. Their innovative platform enables scientists to create new cell-based disease models and conduct high-throughput screening, improving research outcomes in a simplified workflow. StemoniX collaborates with drug discovery organizations, offering in-house screening capabilities and large-scale operationalization of human iPS cells. Their microHeart® and microBrain® products provide researchers with structurally aligned cardiac and brain cells resembling native human tissue, accelerating the development of promising medicines. To learn more about StemoniX's products and services, contact them at [email protected].